Edurne A. A.
- Country
- Spain
- Department
- Oncology
Research Overview
- Dose-Escalation Study of BI 764532 in Patients with DLL3-Positive Small Cell Lung Carcinoma and Neuroendocrine Neoplasms
- Evaluation of the Safety, Tolerability, and Efficacy of the Pan-KRAS Inhibitor LY4066434 in Patients with KRAS Mutant Advanced Solid Tumors
- Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 363 of 611 partner sites.
Specializations
Non-Small Cell Lung Cancer (NSCLC)
The investigator specializes in studying advanced treatments for non-small cell lung cancer, with particular emphasis on targeted therapies and immunotherapy combinations.
- Stage III unresectable NSCLC
- Metastatic NSCLC treatment approaches
- EGFR-mutated NSCLC interventions
Notable focus on combination therapies involving immunotherapy agents and targeted molecular treatments.
Small Cell Lung Cancer (SCLC)
The investigator conducts research in small cell lung cancer treatment modalities, particularly focusing on limited-stage and extensive-stage disease.
- Limited-stage SCLC therapies
- Maintenance treatment strategies
- Novel combination approaches
Expertise in evaluating immunotherapy and chemotherapy combinations for SCLC treatment.
Specialized Therapeutic Approaches
The investigator explores innovative treatment strategies targeting specific molecular pathways and genetic mutations in lung cancer.
- RET fusion-positive treatments
- MET mutation therapies
- PD-L1 targeted approaches
Focus on personalized medicine approaches based on specific genetic and molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.